|Bid||4.7000 x 1800|
|Ask||4.7600 x 3000|
|Day's Range||4.5206 - 4.7800|
|52 Week Range||3.9500 - 77.7700|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
New York, New York--(Newsfile Corp. - September 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme's September 29, 2020 initial public offering (the "IPO" or "Offering"); and/or (2) between September 29, 2020 and June 18, 2021, inclusive, (the "Class Period") of the important September 7, 2021 lead plaintiff deadline in the securities class action.SO ...
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Orphazyme A/S (NASDAQ: ORPH), CorMedix Inc. (NASDAQ: CRMD), Koninklijke Philips N.V. (NYSE: PHG), and Sesen Bio, Inc. (NASDAQ: SESN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the
Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on September 29, 2020 (the "IPO"), or between September 29, 2020 and June 18, 2021, .